Gotham Asset Management LLC Buys 4,178 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Gotham Asset Management LLC raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 47,440 shares of the biopharmaceutical company’s stock after purchasing an additional 4,178 shares during the period. Gotham Asset Management LLC’s holdings in Halozyme Therapeutics were worth $2,268,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Shaker Investments LLC OH raised its position in shares of Halozyme Therapeutics by 12.3% in the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after acquiring an additional 8,249 shares in the last quarter. Foster & Motley Inc. raised its position in shares of Halozyme Therapeutics by 118.6% in the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company’s stock worth $1,113,000 after acquiring an additional 12,630 shares in the last quarter. Jennison Associates LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $731,000. Finally, Koa Wealth Management LLC raised its position in shares of Halozyme Therapeutics by 10.6% in the 4th quarter. Koa Wealth Management LLC now owns 82,407 shares of the biopharmaceutical company’s stock worth $3,940,000 after acquiring an additional 7,924 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Benchmark lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 7th. Morgan Stanley lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $73.00 to $62.00 in a research report on Wednesday. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Finally, Leerink Partners lowered Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a research report on Tuesday. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $61.90.

Halozyme Therapeutics Price Performance

HALO stock opened at $48.95 on Friday. The company has a market capitalization of $6.03 billion, a P/E ratio of 14.27, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The business has a 50-day simple moving average of $60.88 and a two-hundred day simple moving average of $55.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the previous year, the business earned $0.79 EPS. The company’s revenue was up 35.2% compared to the same quarter last year. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 4,497 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director now owns 28,611 shares of the company’s stock, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,697 shares of company stock valued at $1,276,552. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.